



Clinical Image

Gastric Gastrointestinal Stromal Tumor with Pancreatic Invasion: A Rare Presentation

Elisabete Dulce da Cunha Mendes¹, Sara Lourenço Tereso², Rita Afonso Diz³

Received Date:
23-August-2026
Revised Date:
25-August-2026
Accepted Date:
27-August-2026
Published Date:
29-August-2026

¹Resident in Internal Medicine Training, Department of Internal Medicine, Unidade local de Saúde do Alto Alentejo – Hospital de Portalegre, Portalegre, Portugal, ORCID: <https://orcid.org/0000-0002-1994-7849>.

²Resident in Internal Medicine Training, Department of Internal Medicine, Unidade Local de Saúde do Oeste – Hospital Caldas da Rainha, Caldas da Rainha, Portugal; ORCID: <https://orcid.org/0000-0001-9503-7049>.

³Consultant in Internal Medicine, Master's Degree in Medicine, Department of Internal Medicine, Unidade Local de Saúde do Nordeste. Unidade Hospitalar de Bragança, Bragança, Portugal; ORCID: <https://orcid.org/0000-0002-8707-3952>.

Corresponding Author:

Elisabete Dulce da Cunha Mendes,
Internal Medicine Resident, Medical
Degree, Department of Internal
Medicine, Unidade Local de Saúde do
Norte Alentejano, Hospital de
Portalegre, Portalegre, Portugal,
ORCID: <https://orcid.org/0000-0002-1994-7849>.

Citation:

Elisabete Dulce da Cunha Mendes,
Sara Lourenço Tereso, Rita Afonso Diz
(2026). Gastric Gastrointestinal
Stromal Tumor with Pancreatic
Invasion: A Rare Presentation. *Euro J
Case Rep Clin Imag.* 2026; August,
e22,1-4.

Copyrights:

© Elisabete Dulce da Cunha Mendes,
2026,
et al., This article is licensed under the
Creative Commons Attribution-Non
Commercial-4.0-International-
License-(CCBY-NC)
(<https://europeanjournalofcasereports.com/blogpage/copyright-policy>).
Usage and distribution for commercial
purposes require written permission.

Image Case Presentation:

Gastrointestinal stromal tumours (GISTs) are mesenchymal neoplasms that most commonly arise in the stomach and may occasionally reach an exceptionally large size and invade adjacent organs. Their management depends on tumour extent, metastatic disease and molecular characteristics, with tyrosine kinase inhibitors playing a central role in advanced disease [1-3].

We present the case of a 65-year-old woman who presented with several weeks of nausea, vomiting and significant weight loss. Physical examination revealed a large, painless abdominal mass. Computed tomography (CT) demonstrated a heterogeneous intra-abdominal mass measuring approximately 28 cm, with extensive central necrosis and peripheral enhancing soft tissue, displacing the stomach, spleen, bowel and other abdominal structures; the pancreas could not be clearly delineated (Figure 1).

Keywords:

- Gastric Gastrointestinal Stromal Tumour
- GIST
- Gastric Tumour
- Pancreatic Invasion
- Computed Tomography



Figure 1: Initial contrast-enhanced abdominal computed tomography, sagittal reconstruction, demonstrating a giant heterogeneous intra-abdominal mass occupying most of the abdominal cavity, with extensive central low attenuation and a peripheral enhancing soft-tissue component.

The patient underwent extensive en bloc resection, including near-total gastrectomy, distal pancreatectomy, splenectomy, left colectomy and cholecystectomy. Histopathological examination demonstrated a 30-cm high-grade gastric GIST with pancreatic invasion (pT4N0M1R1). Immunohistochemistry was positive for

CD34, CD117 and DOG1, and three peritoneal metastatic nodules were identified. Imatinib therapy was initiated. Two years later, CT demonstrated extensive recurrent disease, with a 20 × 10 cm partially necrotic subhepatic mass invading the liver parenchyma and hepatic hilum (Figure 2).



Figure 2: Follow-up contrast-enhanced abdominal computed tomography, coronal reconstruction, demonstrating extensive recurrent disease as a large subhepatic mass with invasion of the liver parenchyma and hepatic hilum.

The recurrence was considered unresectable and the patient was referred for palliative care. This case illustrates the potential for gastric GISTs to reach an enormous size, invade adjacent organs and recur despite

treatment. Cross-sectional imaging is essential for defining tumour extent, assessing resectability and monitoring disease progression.

Declarations:

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Informed consent for publication was obtained from the patient's legal guardians.

Data Availability Statement: No new data were created or analyzed in this study. Data sharing is not applicable to this article.

Acknowledgments: Not applicable.

Conflicts of Interest: We confirm that there are no conflicts of interest to declare.

References:

1. Casali PG, Blay JY, Abecassis N, et al. Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2022;33(1):20–33. DOI: <https://doi.org/10.1016/j.annonc.2021.09.005>
2. von Mehren M, Kane JM, Riedel RF, et al. NCCN Guidelines® Insights: Gastrointestinal Stromal Tumors, Version 2.2022. *J Natl Compr Canc Netw.* 2022;20(11):1204–1214. DOI: [10.6004/jnccn.2022.0058](https://doi.org/10.6004/jnccn.2022.0058).
3. Serrano C, Álvarez R, Carrasco JA, et al. SEOM-GEIS clinical guideline for gastrointestinal stromal tumors (2022). *Clin Transl Oncol.* 2023;25(9):2707–2717. DOI: [10.1007/s12094-023-03177-7](https://doi.org/10.1007/s12094-023-03177-7).



Submit your manuscript to the
European Journal of Case Reports and Clinical Images
(ISSN: 3070-3344)

and benefit from:

- + Convenient online submission
- + Rigorous peer review
- + Immediate publication on acceptance
- + Open access: articles freely available online
- + High visibility within the field
- + Retaining the copyright to your article

Submit your manuscript at

<https://europeanjournalofcasereports.com/>
&

Email: submission@europeanjournalofcasereports.com